Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Group Says FDA Should Have Emphasized Auditing More Than Testing for Melamine

This article was originally published in The Gold Sheet

Executive Summary

FDA criticized for stressing testing rather than auditing in melamine guidance

You may also be interested in...



FDA Identifies Excipients At Risk for Potential Melamine Contamination

Which excipients might be vulnerable to melamine substitution? FDA provides its list of 23 at-risk excipients and recommends specific steps for safeguarding them.

FDA Offers More Flexibility on Residual Solvents in Generic Drug Applications

More flexibility on residual solvents obtained from FDA's Office of Generic Drugs.

McKinsey Survey Highlights Progress, Challenges in Adoption of QbD

Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.

Latest News
See All
UsernamePublicRestriction

Register

PS000420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel